Suppr超能文献

与传统组织病理学因素相比,增殖细胞核抗原和c-erbB-2在乳腺癌中的预后价值。

Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer.

作者信息

Schönborn I, Zschiesche W, Minguillon C, Spitzer E, Möhner M, Ebeling K, Grosse R

机构信息

Department of Gynecology and Obstetrics, University Hospital Rudolf Virchow Charlottenburg, Freie Universität Berlin, Germany.

出版信息

J Cancer Res Clin Oncol. 1995;121(2):115-22. doi: 10.1007/BF01202223.

Abstract

Expression of proliferating cell nuclear antigen (PCNA) and c-erbB-2 oncoprotein has been assessed in 471 women with breast cancer to evaluate their prognostic value as compared to conventional histopathological factors. In univariate analysis, high PCNA expression (> or = 20%) predicted a significantly worse survival in lymph-node-negative tumors (univariate P = 0.031). However, the effect disappeared in multivariate analysis and the histological grade remained the only independent factor for this group. Despite its close correlation to histological grade (P < 0.001), PCNA expression discriminated subsets with different survival within the heterogeneous group of moderately differentiated tumors (univariate P = 0.073, multivariate P = 0.075). PCNA expression was not found to be a significant prognostic factor in lymph-node-positive tumors, thus it was of limited value for breast cancer patients as a whole. c-erbB-2 protein overexpression was associated with a worse survival (univariate P = 0.019, multivariate P = 0.057) for the entire group of patients. The effect was mainly attributed to the significance of c-erbB-2 as an independent factor in lymph-node-positive (up to three nodes, multivariate P = 0.04; four or more nodes: multivariate P = 0.017) and large tumors (> 2 cm: multivariate P = 0.002). c-erbB-2 was without significance in lymph-node-negative patients. Though both factors might amplify the prognostic information for distinct patient subsets they do not achieve the strong prognostic value of conventional histopathological features in breast cancer.

摘要

对471例乳腺癌女性患者的增殖细胞核抗原(PCNA)和c-erbB-2癌蛋白表达进行了评估,以评价其与传统组织病理学因素相比的预后价值。单因素分析中,PCNA高表达(≥20%)预示淋巴结阴性肿瘤患者的生存率显著更差(单因素P = 0.031)。然而,多因素分析中该效应消失,组织学分级仍是该组唯一的独立因素。尽管PCNA表达与组织学分级密切相关(P < 0.001),但在中度分化肿瘤的异质性组中,PCNA表达可区分不同生存亚组(单因素P = 0.073,多因素P = 0.075)。在淋巴结阳性肿瘤中,未发现PCNA表达是显著的预后因素,因此其对乳腺癌患者总体价值有限。c-erbB-2蛋白过表达与整个患者组的较差生存相关(单因素P = 0.019,多因素P = 0.057)。该效应主要归因于c-erbB-2作为淋巴结阳性(最多3个淋巴结,多因素P = 0.04;4个或更多淋巴结:多因素P = 0.017)和大肿瘤(> 2 cm:多因素P = 0.002)的独立因素的意义。c-erbB-2在淋巴结阴性患者中无意义。尽管这两个因素可能会增强不同患者亚组的预后信息,但它们并未达到乳腺癌传统组织病理学特征的强大预后价值。

相似文献

7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验